SYDNEY — One of the few randomized phase 3 trials ever conducted in mesothelioma has found that keyhole surgery did not improve survival when compared with the standard treatment of talc pleurodesis.

Imfinzi plus chemotherapy improved overall survival, progression-free survival, and objective response rates in advanced pleural mesothelioma compared to chemotherapy alone. Slow patient enrollment ...

Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published ...

- 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is Approximately 28 Weeks - - ...

Mesothelioma symptoms near death worsen as the cancer spreads and organs fail. Learn about the final stages of mesothelioma and how it kills.

A new research paper titled "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable ...

(September 2, 2025—Denver, Colo) Researchers working independently at the University of Hawaii Cancer Center and the National Cancer Institute have discovered, and validated, a new variant of ...

Mesothelioma, an aggressive and fatal cancer, continues to affect thousands of Americans, but veterans remain among the hardest affected. The main issue for affected veterans is that mesothelioma is ...